Can oncologists add?

M. E. Lippman

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


In the present study, rather convincing evidence for an alternative mechanism of antiestrogen action through a non-receptor-mediated pathway is provided. Antiestrogens are shown to alter cytotoxicity of melphalan and fluorouracil without themselves exerting growth inhibitory effects. While the mechanism(s) of this remain to be determined, these studies should provide several important caveats to clinical investigators. First, empirical drug combinations should not be assumed to increase activity. Whenever possible scheduling and drug combinations should be rationally explored in vitro and in animal models. Second, other molecular sites of action aside from the high-affinity estrogen receptor must clearly exist for antiestrogens and their role as targets for therapeutic intervention need to be explored. Whether these will turn out to be the ubiquitous but undefined antiestrogen binding sites previously described will await further study.

Original languageEnglish (US)
Pages (from-to)698-699
Number of pages2
JournalJournal of Clinical Oncology
Issue number6
StatePublished - Jan 1 1989

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Can oncologists add?'. Together they form a unique fingerprint.

Cite this